Projects

BCS2 is currently advancing a diverse pipeline of "Super Generic" reformulations that leverage AI-driven solvent engineering to improve the performance of established drugs. A primary commercial success includes the development of oral sprays and dissolvable films for erectile dysfunction, such as Vardenafil and Tadalafil, which achieve up to a 35,000-fold increase in solubility and a 15-minute onset of action. The company is also targeting the central nervous system with a tetrahydrocurcumin nasal spray for dementia. Additionally, the portfolio features high-value anticoagulant reformulations for Apixaban and Rivaroxaban to aid stroke prevention in patients with swallowing difficulties, alongside Hydromorphone films for palliative pain management and Fisetin-based senolytic treatments for longevity.